The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

For what’s ahead

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

What to expect

Treatments in development

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

About our Pipeline

Focused treatment

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Learn the science

Clinical trials

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Splash trial

News + Stories

See All
Press Release
25 May
2023

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

PNT2004 program’s phase 1 FRONTIER trial design to be presented. Abstract to be released at 5:00 PM ET, May 25th. Poster to be available starting at 9:00 AM ET, June 3rd.

Press Release
15 May
2023

POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023. Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp.

All news + stories